Stockscreener 앱 받기
4.80
2.04%
-0.10
시간 외 거래:
4.85
0.05
+1.04%
전일 마감가:
$4.90
열려 있는:
$4.86
하루 거래량:
85,802
Relative Volume:
0.39
시가총액:
$147.03M
수익:
$50.14M
순이익/손실:
$-35.38M
주가수익비율:
-3.4286
EPS:
-1.4
순현금흐름:
$-39.46M
1주 성능:
-3.23%
1개월 성능:
+25.00%
6개월 성능:
+9.59%
1년 성능:
-42.65%
1일 변동 폭
$4.7152
$4.985
1주일 범위
$4.64
$5.13
52주 변동 폭
$3.22
$10.29
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.80 | 150.10M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
110.25 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.78 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.97 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.63 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Northland Capital | Outperform |
| 2025-11-20 | 업그레이드 | BTIG Research | Sell → Neutral |
| 2025-08-08 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
Northland Securities Predicts Avita Medical Q1 Earnings - National Today
Growth Recap: Can AVITA Medical Inc maintain sales growthJuly 2025 Pullbacks & Verified Entry Point Signals - baoquankhu1.vn
Avita Medical (NASDAQ:RCEL) Now Covered by Analysts at Northland Securities - MarketBeat
Avita Medical at TD Cowen Conference: Growth and Strategic Focus By Investing.com - Investing.com Canada
RCEL SEC FilingsAvita Medical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RCELAVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - ADVFN Ltd
RCEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Trends: Can AVITA Medical Inc weather a recession2025 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade - Zacks Investment Research
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year - MarketBeat
Wall Street experts predict Avita Medical (RCEL) may surge by 29.87%: Here’s how you can approach trading - Bitget
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference - Investing News Network
Avita Medical (NASDAQ:RCEL) CFO David O'toole Purchases 3,000 Shares of Stock - MarketBeat
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 earnings call transcript - MSN
AVITA Medical (RCEL) CFO awarded RSU and stock option grants - Stock Titan
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Scar Treatment Market Size is Expected to Reach USD 56.30 Billion by 2033; Growth is Propelling Due to the Surging Awareness for Advanced Cosmetic and Reconstructive Procedures Globally - GlobeNewswire Inc.
RCEL: D. Boral Capital Maintains "Buy" Rating and $10 PT | RCEL Stock News - GuruFocus
Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Broker tips 25% upside for this ASX healthcare stock following FY25 earnings results - MSN
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth - Investing.com Nigeria
Avita Medical Earnings Call Signals Stabilizing Growth - The Globe and Mail
Avita Medical (RCEL) TTM US$48.6m Loss Tests Bullish Profitability Narratives - simplywall.st
Avita's Road to Profitability Is in Sight - Morningstar
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026 - Investing.com Canada
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth By Investing.com - Investing.com South Africa
AVITA Medical (RCEL) Reports Strong Q4 2025 Performance - GuruFocus
Avita Medical Q4 Earnings Call Highlights - MarketBeat
AVITA Medical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AVITA Medical (RCEL) Q4 2025 Earnings Transcript - The Globe and Mail
RCEL Refines Financial Strategy with New Credit Facility - GuruFocus
Avita Medical (RCEL) Reports Lower Q4 Revenue Amidst Operational Transition - GuruFocus
Avita Medical earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
AVITA Medical to Announce Q4 Earnings on February 12 - Intellectia AI
Avita Medical (NASDAQ:RCEL) Issues Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical Q4 Earnings Summary & Key Takeaways - Benzinga
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Lake Street raises price target on AVITA Medical, Inc. (RCEL) to $3.50, maintains hold rating - MSN
Is AVITA Medical Inc. forming a bullish divergenceEarnings Recap Summary & Fast Entry and Exit Trade Plans - mfd.ru
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Is AVITA Medical Inc. stock a buy before product launchesTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
Aug Volume: What is the dividend yield of GOOSJuly 2025 EndofMonth & Verified Entry Point Signals - baoquankhu1.vn
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating - Finviz
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.21%
0.24%
자본화:
|
볼륨(24시간):